Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Approval Recommendations Set Path For Pfizer’s Xeljanz, Japan Tobacco’s HIV Therapy In Japan

This article was originally published in PharmAsia News

Executive Summary

JT’s HIV compound comes home after being joined with Gilead combination therapy. Also approved is Nobelpharma’s glowing red in vivo diagnostic for malignant glioma.


Related Content

Gilead Compares Stribild To Prezista In Seeking Exclusivity For Fixed Dose Combinations
Pfizer’s Tofacitinib Clears FDA Without Limited Indication


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts